Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.95 USD | -1.97% | -10.57% | +61.59% |
May. 14 | Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 30 | North American Morning Briefing : More Earnings -2- | DJ |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 1.01M | Capitalization | 245M |
---|---|---|---|---|---|
Net income 2024 * | -77M | Net income 2025 * | -103M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 243 x |
P/E ratio 2024 * |
-3.21
x | P/E ratio 2025 * |
-2.89
x | Employees | 60 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 59.72% |
1 day | -1.97% | ||
1 week | -10.57% | ||
Current month | -12.54% | ||
1 month | -6.03% | ||
3 months | +86.62% | ||
6 months | +107.03% | ||
Current year | +61.59% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 18-03-31 | |
Kristina Masson
FOU | Founder | 44 | 18-02-28 |
Director of Finance/CFO | 53 | 22-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 55 | Feb. 07 | |
Sharon Shacham
BRD | Director/Board Member | 53 | 20-09-30 |
Chief Executive Officer | 62 | 18-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +4.20% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 7.95 | -1.97% | 52,182 |
24-05-23 | 8.11 | -5.37% | 65,057 |
24-05-22 | 8.57 | +4.38% | 51,671 |
24-05-21 | 8.21 | -3.98% | 44,437 |
24-05-20 | 8.55 | -3.82% | 60,214 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+61.59% | 245M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- ACRV Stock